Serum phosphate levels and mortality risk among people with chronic kidney disease.
By B. Kestenbaum, J. Sampson, K. Rudser, D. Patterson, S. Seliger, B. Young, D. Sherrard, D. Andress. Journal of the American Society of Nephrology, 2005
1,232 citations recorded by the source corpus.
Subfields: Nephrology, Nutrition and Dietetics, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/acdb89dab1a633a6eb8ef786cd36ae161724cb9f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Nephrology
In Nutrition and Dietetics
Citations in the corpus
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients with Chronic Kidney Disease (2011, background): “the normal range.(2,3) However, small studies suggest that an elevated FGF-23 level is an independent risk factor for mortality among patients undergoing dialysis,(4,5) and for more rapid loss of kidney function in earlier stages of chronic kidney disease.”
- Calcium metabolism in health and disease. (2010, background): “mortality (34), which can be predicted from the levels of serum phosphate and calcium-phosphate product (35).”
- Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. (2007, background): “Elevated PTH is known to cause cardiomyocyte damage in animals with CKD(21) and parathyroidectomy in dialysis patients is associated with reductions in left ventricular hypertrophy(22) and in cardiovascular mortality.(23) Thus, taken together we may speculate that low 1,25 OH2 D3 and elevated iPTH l”